Fuzeon (Enfuvirtide)

Enfuvirtide is a special medicine used to treat HIV. It works by stopping the virus from entering your cells. It's usually given along with other HIV medications as part of a treatment plan to help manage the infection.

Brand names:Fuzeon
Medication

What people taking Fuzeon (Enfuvirtide) report

Every report comes from a Lived member, sent anonymously.

Have you tried Fuzeon (Enfuvirtide) for HIV Infection?

NameHow it went

About Fuzeon (Enfuvirtide)

What It's For

Enfuvirtide, sold under the brand name Fuzeon, is an injectable medicine for HIV (human immunodeficiency virus) in people who have already taken several HIV treatments and whose virus keeps multiplying despite their current regimen. It is approved for adults and for children who weigh at least 11 kilograms (about 24 pounds), and it is always used together with other HIV medicines, never on its own. It treats HIV-1, the common type of HIV, and does not work against HIV-2. Enfuvirtide, approved in 2003, is the only medicine in the group called fusion inhibitors. Records of the US Food and Drug Administration (FDA) and the National Institutes of Health (NIH) HIVinfo list of approved HIV medicines now show the Fuzeon brand as discontinued in the United States, and no generic version is listed. Several newer HIV medicines that block other steps of the virus's life cycle have been approved since, and an HIV specialist chooses among the options using the person's treatment history and resistance testing.

How It Works

HIV has to get inside CD4 cells, a type of white blood cell that coordinates the immune response, in order to copy itself. To enter, the virus first attaches to the cell's surface, and then a viral protein called gp41 folds back on itself and pulls the virus's outer envelope and the cell's membrane together so they fuse. Enfuvirtide is a lab-made chain of 36 amino acids (a peptide) that matches part of gp41. It binds to gp41 and stops that folding step, so the virus cannot fuse with the cell and deliver its genetic material inside. Because this is a different step from the ones targeted by most HIV pills, HIV that has become resistant to older drug classes usually remains sensitive to enfuvirtide. HIV can still develop resistance to enfuvirtide itself through changes in gp41, which is why it has to be paired with other medicines that are still active against the person's virus.

Dosage & Administration

Enfuvirtide comes as a powder in single-use vials. Each dose is mixed with 1 mL of sterile water, left to dissolve completely (this can take up to 45 minutes), and injected under the skin of the upper arm, the front of the thigh or the abdomen. The adult dose is 90 mg twice a day. Children's doses are based on weight and are adjusted as they grow, up to the adult dose. People learn to prepare and give the injections from a health professional, and the first injection is done under supervision. Each injection goes in a different spot, away from any area still reacting to an earlier dose, and away from places where nerves run close to the skin (near the elbow, knee, groin or the lower or inner buttock), the navel, moles, scars, tattoos, bruises or visible blood vessels. A mixed dose that is not used right away can be kept in its vial in the refrigerator and must be used within 24 hours. Used needles go in a puncture-resistant container. A caregiver who gets a needle stick after giving an injection should contact a health professional right away. Do not change the dose or schedule, or stop enfuvirtide or any other HIV medicine, without talking to the HIV care team.

Side Effects

Reactions where the medicine is injected are almost universal: in the main trials, 98% of people had at least one. They usually include pain, redness, itching, bruising, and firm lumps or small cysts under the skin. They typically start in the first week and keep happening throughout treatment, and individual spots often last several days or longer, so several can be present at once. Rotating injection sites helps. About 4% of trial participants stopped because of these reactions and another 3% because of the burden of injecting. A small number of people develop an infected injection site. Increasing warmth, spreading redness, swelling, pus or drainage at a site should be reported to the care team promptly. Diarrhea, nausea and tiredness were also common in trials, though people on other HIV medicines alone had them too. Two uncommon problems need medical attention right away. A whole-body allergic reaction, affecting fewer than 1 in 100 people, can cause combinations of rash, fever, nausea and vomiting, chills or shaking, and feeling faint from low blood pressure. If it happens, stop the injections and get medical care immediately, and do not restart enfuvirtide afterward. Bacterial pneumonia was also more common in people taking enfuvirtide in the trials, although it is not certain the medicine caused it; cough with fever, fast breathing or shortness of breath should be checked by a clinician right away.

Interactions & Warnings

Enfuvirtide is not broken down by the liver enzymes that cause many HIV drug interactions, and its label does not call for dose changes with other medicines. The interaction that matters most is practical: people taking a blood thinner, or who have hemophilia or another bleeding disorder, may bleed more after injections. Enfuvirtide should never be the only active medicine in a regimen. Used alone, or alongside medicines the virus already resists, HIV can quickly become resistant to it. A needle-free injection device called the Biojector 2000 was once used with enfuvirtide; it was linked to bruising, collections of blood under the skin, and nerve pain lasting up to six months when used near large nerves. As with other HIV treatment, when the immune system starts to recover it can react strongly to infections already hiding in the body, a reaction called immune reconstitution syndrome. New symptoms after starting a stronger regimen are worth reporting. Pregnancy data are too limited to judge enfuvirtide's risk, and breastfeeding is not recommended while taking it.

What to Expect

Enfuvirtide is added to a regimen that has been rebuilt around other medicines the virus still responds to. Progress is tracked with two blood tests. The viral load measures how many copies of HIV are in each milliliter of blood, and the usual goal is to get it below the level standard tests can detect (generally under 50 copies). The CD4 count measures the immune cells HIV destroys; a rising count means the immune system is recovering. In the main trials, which enrolled people who had already taken a median of 12 HIV medicines, 23% of those who added enfuvirtide reached an undetectable viral load after 48 weeks, compared with 8% of those who did not, and their CD4 counts rose about twice as much. Many people did not reach an undetectable level, which reflects how hard their HIV was to treat. The twice-daily injections and ongoing skin reactions are the main burden of daily life on enfuvirtide. Because the brand is listed as discontinued in the US, anyone currently relying on it should ask the HIV specialist about supply and about switching to a newer option before running short, so that the regimen is never interrupted.

Questions to Ask Your Doctor

  1. 1.Is enfuvirtide still available to me, and if not, which newer medicine would replace it in my regimen?
  2. 2.What did my resistance test show, and which other medicines in my regimen are still active against my HIV?
  3. 3.How should I manage injection site reactions, and which changes at a site mean I should call you?
  4. 4.When will we check my viral load and CD4 count, and what result would tell us this regimen is working?
  5. 5.I take a blood thinner (or have a bleeding disorder); what should I do differently when injecting?

Last reviewed • Oct 2026

Educational content, not medical advice.